Cannabis Law Report

MAY 19, 2022

This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.

Therapy 52

Therapy Treatment Clinical Trials Access 52

Cannabis Law Report

MAY 10, 2022

More than half of all prescriptions for medicinal cannabis in Australia are written by doctors in Queensland, with prescriptions often given for conditions there is little evidence medicinal cannabis can treat, new research reveals. We are aware of clinical trials in that space, but not strong evidence.”.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

AUGUST 10, 2022

According to CAMH’s lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce “ sustained antidepressant effects” in individuals living with severe depression. Optimi Health Corp.

Clinical Trials 52

Clinical Trials Research and Development Therapy Microdosing 52

Cannabis Law Report

AUGUST 7, 2021

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

Cannabis Law Report

JULY 13, 2022

“Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”.

Therapy 52

Therapy Clinical Trials Microdosing Research and Development 52

Cannabis Law Report

AUGUST 14, 2021

The deal signed in March had sought to progress an over-the-counter medicine with the TGA using Emyria’s EMD-003 program and Cann’s Gelpell technology. Cann Group (CAN) and Emyria (EMD) mutually agree to drop a deal for the proposed registration of a Schedule 3 cannabidiol (CBD) product.

CBD 105

CBD Clinical Trials Programs Food 105

Cannabis Law Report

SEPTEMBER 10, 2021

This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinical trials.”.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

JUNE 11, 2021

NEW YORK, June 9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Here’s the press release.

Clinical Trials 95

Clinical Trials Research and Development Pharmaceutical Medicine 95

Cannabis Law Report

FEBRUARY 24, 2022

Thus, providing a new pathway for patients to access psychedelic treatment, and another example of the medicinal approach to psychedelic legalization. Timeline of Medicinal Legalization in Canada. The changes to the FDR and CDSA do not outright legalize MDMA or psilocybin for medicinal use. Subsection 56(1) Exemption.

Therapy 52

Therapy Access Clinical Trials Treatment 52

Cannabis Law Report

DECEMBER 9, 2021

The Company believes it has produced a sufficient supply of cGMP DMT to complete its planned Phase 1 and Phase 2 clinical trials. as medical consultants to the Company’s DMT stroke clinical research program. in the latter part of 2022, after the Phase 1 trial has been completed. Dr. Anthony Rudd.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

MMJ Recs

DECEMBER 17, 2023

The Texas Compassionate Use Program (TCUP) represents the Lone Star State’s cautious foray into the realm of medical marijuana. Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals.

Law 52

Law Dispensary Clinical Trials Programs 52

Cannabis Law Report

MARCH 2, 2020

The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. In lockstep with the FDA’s more open-minded approach toward psychedelic medicine, Denver, Oakland, and Santa Cruz all decided to decriminalize magic mushrooms. Hundreds of other U.S.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

SpeedWeed

AUGUST 11, 2021

“This grant enables more rigorous study, overseen by the FDA, which may lead to cannabis flower becoming prescribable medicine someday. The grant comes from Michigan’s 2021 Veteran Marijuana Research Grant Program , and is funded by the state’s recreational cannabis taxes. MAPS Makes History.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

NOVEMBER 19, 2021

MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. We are committed to continuing to lead the field of psychedelic medicine with integrity and ethics at the core. Why work for MAPS Public Benefit Corporation (MAPS PBC)?

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

JUNE 23, 2021

. “Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic drugs, therapies, and enabling technologies to treat Addiction, and delivering psychedelic treatments for Addiction in our clinics,” said Awakn CEO, Anthony Tennyson. David Nutt), starts in Q4 2021.

Clinical Trials 110

Clinical Trials Therapy Research and Development Treatment 110

Cannabis Law Report

OCTOBER 2, 2021

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

SpeedWeed

SEPTEMBER 17, 2021

Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. Wesana outlined five key goals: Gain expertise and information to design psychedelic-assisted therapy programs for TBI and improve the Wesana timeline and path to market for its treatments.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

MAY 29, 2022

This is a natural medicine. They’re creating medicine synthetically, and giving it to people to do exactly what this can do. I think it’s incredible that here in Princeton, BC.This is the pinnacle of this medicine coming to fruition naturally,” Henderson said. I want people to be excited about natural medicine.

Research and Development 52

Research and Development Clinical Trials Medicine Access 52

The Cannigma

OCTOBER 14, 2022

San Marino medical marijuana program. Established in 2016 by a citizen’s initiative, patients can purchase cannabis-based medicines like Sativex to treat a number of approved conditions including multiple sclerosis, spine injuries, and neuropathic pain. The program does not include cannabis flower or home grow.

Law 56

Law Clinical Trials Research and Development Recreational 56

Cannabis Law Report

AUGUST 17, 2021

The FDA’s Office of Orphan Drug Products grants orphan status to support the development of medicines for rare disorders that affect fewer than 200,000 people in the U.S. Conference Call and Webcast Details.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Canna Law Blog

NOVEMBER 27, 2021

Medicines and Healthcare Products Regulatory Agency for one of its DMT products for the treatment of major depressive disorder. In fact, Small Pharma has been conducting trials as reported by the BBC and expanded its clinical trial this past summer. Last July, researchers published a study of the use of DMT to treat U.S.

Therapy 88

Therapy Clinical Trials DEA Microdosing 88

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. Exploring CBD for Medical Use As interest in CBD grows, researchers are continuously exploring its potential applications in the medical field.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

SEPTEMBER 1, 2021

CYBN ) is a Toronto-based psychedelic medicine firm. The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. At the moment, MindMed is hands-down the industry leader in LSD-inspired medicines.

Research and Development 102

Research and Development Therapy Clinical Trials Pharmaceutical 102

Cannabis Law Report

NOVEMBER 22, 2021

Andrew Forrest tips $5 million into medicinal cannabis company. Andrew Forrest is the latest billionaire to enter the medicinal cannabis arena with a $5 million share placement by his family’s investment arm Tattarang into Perth-based health technology company Emyria. The Sydney Morning Herald reports.

Clinical Trials 52

Clinical Trials Treatment Medicine Cannabinoids 52

Cannabis Law Report

FEBRUARY 9, 2022

The medicinal cannabis producer believes the move would be in the “best interest” of shareholders and will allow Reset to “pursue its strategy as a standalone company.”. We are confident the demerger will allow for both Reset to drive its psychedelics strategy and LGP to focus solely on its medicinal cannabis business. “We

Clinical Trials 52

Clinical Trials Research and Development Medicine Business 52

Cannabis Law Report

JULY 24, 2021

At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. “The It is our belief that the tailoring of the properties of these compounds will vastly improve their utility to medicine and therapy.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Veriheal

MAY 26, 2022

But one area of cannabis medicine is still lagging behind—research. states pass relevant legislation and educating doctors about the power of cannabis medicine. In addition to the large uptick in registrants, we saw an even larger influx of new visitors to our site, enabling them to learn more about our research program.”.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website. territories. This means that U.S.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

JULY 25, 2022

Psychedelics, medicine and ethics has always been a tricky thing and we’re suprised (or maybe not) that those who have held themselves up to be the paragons of perfection in the field over the past few years, have in fact been either arrogant, dumb or lazy when it comes to managing ethics at their organisations.

Medicine 52

Medicine Therapy Research and Development Business 52

SpeedWeed

MAY 22, 2021

The US Food and Drug Administration (FDA) has just approved a new clinical trial that will allow therapists to legally use MDMA. For this Phase 1 trial, MAPS will recruit 150 therapists that are currently being trained to conduct MDMA-assisted therapy sessions for PTSD. .

Clinical Trials 52

Clinical Trials Therapy Legalization Research and Development 52

Cannabis Law Report

OCTOBER 13, 2021

Filed in support of the Company’s CYB004 pre-clinical development program, the PCT filing serves to increase the Company’s library of drug delivery modalities directed to optimal delivery of psychedelics and further strengthens Cybin’s growing IP portfolio. Vigorous scientific research and clinical trials are needed.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

The Cannigma

MAY 19, 2021

Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.

Law 137

Law Legalization Clinical Trials CBD 137

Puff Puff Post

OCTOBER 3, 2019

In a 47 acre greenhouse – close to the size of 42 football fields – GW is developing and delivering strains of medicinal cannabis. Leading the pilot research project is Dr. Eric Hollander, director of the Autism and Spectrum Program and Anxiety and Depression Program at Montefiore Hospital.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

Cannabis Law Report

OCTOBER 5, 2021

The Panel’s report will be considered by the Advisory Committee of Medicines Scheduling (ACMS) at the 3 November 2021 meeting. The review excludes pre-clinical trials (i.e. He obtained fellowship of the relevant Colleges in the UK, Australasia and Canada, as well as of the Australasian Chapter of Addiction Medicine.

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

SpeedWeed

JULY 6, 2021

This new program is being funded by private investors, including Matt Wullenweg, developer of WordPress, and philanthropist Tim Ferriss. Professor Marks also serves on the Oregon Psilocybin Advisory Board, an agency tasked with overseeing the country’s first legal therapeutic psilocybin program. View original article.

Policy 52

Policy Law Research and Development Therapy 52

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Veriheal

AUGUST 31, 2020

These students showed knowledge and passion for the future of cannabis and posed revolutionary ideas rooted in their training across business, agriculture, biochemistry, public health, pharmacology, medicine, and liberal arts. . Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”.

Research and Development 117

Research and Development Education Agriculture Patients 117